Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PLD2 | O14939 | 1/20 | 0.43 |
| ▸ | PLD1 | Q13393 | 1/20 | 0.43 |
| ▸ | EGFR | P00533 | 3/20 | 0.43 |
| ▸ | PIK3CA | P42336 | 3/20 | 0.43 |
| ▸ | NPC1 | O15118 | 3/20 | 0.42 |
| ▸ | RAB9A | P51151 | 2/20 | 0.42 |
| ▸ | RXFP1 | Q9HBX9 | 2/20 | 0.42 |
| ▸ | NHERF1 | O14745 | 3/20 | 0.41 |
| ▸ | PYGL | P06737 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | ROCK2 | O75116 | 2/20 | 0.41 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.41 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.41 |
| ▸ | HDAC2 | Q92769 | 2/20 | 0.40 |
| ▸ | HRAS | P01112 | 2/20 | 0.40 |
| ▸ | ESR1 | P03372 | 2/20 | 0.40 |
| ▸ | ESR2 | Q92731 | 2/20 | 0.40 |
| ▸ | TP53 | P04637 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5889682 | 0.93 | PLD2 (0.45) | PLD2PLD1EGFRPIK3CANPC1 | |
| SCHEMBL5889465 | 0.88 | PLD2 (0.47) | PLD2PLD1EGFRPIK3CANPC1 | |
| SCHEMBL5680470 | 0.87 | NHERF1 (0.48) | PLD2PLD1EGFRPIK3CANPC1 | |
| SCHEMBL5675889 | 0.84 | ITGB3 (0.42) | PLD2PLD1EGFRPIK3CANPC1 | |
| SCHEMBL5896912 | 0.82 | NHERF1 (0.51) | PLD2PLD1EGFRPIK3CANPC1 | |
| SCHEMBL5676056 | 0.79 | ITGB3 (0.43) | PLD2PLD1EGFRPIK3CANPC1 | |
| SCHEMBL5896610 | 0.79 | ITGB3 (0.40) | PLD2PLD1NPC1RAB9ARXFP1 | |
| SCHEMBL5675941 | 0.79 | ITGB3 (0.44) | PLD2PLD1EGFRPIK3CANPC1 | |
| SCHEMBL5680056 | 0.78 | ITGB3 (0.41) | PLD2PLD1EGFRPIK3CANPC1 | |
| SCHEMBL5680346 | 0.78 | ITGB3 (0.44) | PLD2PLD1EGFRPIK3CANPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7064218-B2 | Aromatic compounds and poly(oxyalkylene) containing aromatic compounds possessing antibacterial, antifungal or antitumor activity | GENELABS TECHNOLOGIES, INC. (US) | 2006-06-20 | — | — | US | disclosed |
| US-6906103-B2 | Compounds possessing antibacterial, antifungal or antitumor activity | GENELABS TECHNOLOGIES, INC. (US) | 2005-06-14 | — | — | US | disclosed |
| US-6849713-B2 | Compounds possessing antibacterial, antifungal or antitumor activity | GENELABS TECHNOLOGIES, INC. (US) | 2005-02-01 | — | — | US | disclosed |
| US-20030212113-A1 | Novel aromatic compounds and poly(oxyalkylene) containing aromatic compounds possessing antibacterial, antifungal or antitumor activity | GLAXOSMITHKLINE LLC | 2003-11-13 | — | — | US | disclosed |
| US-20030119749-A1 | Novel compounds possessing antibacterial, antifungal or antitumor activity | SMITHKLINE BEECHAM CORPORATION | 2003-06-26 | — | — | US | disclosed |
| EP-1294713-A2 | COMPOUNDS POSSESSING ANTIBACTERIAL, ANTIFUNGAL OR ANTITUMOR ACTIVITY | GENELABS TECHNOLOGIES, INC. (US) | 2003-03-26 | — | — | EP | disclosed |
| WO-2002000650-A9 | NOVEL COMPOUNDS POSSESSING ANTIBACTERIAL, ANTIFUNGAL OR ANTITUMOR ACTIVITY | GENELABS TECH INC (US) | 2003-03-06 | — | — | WO | disclosed |
| US-20020037856-A1 | Novel compounds possessing antibacterial, antifungal or antitumor activity | GENELABS TECHNOLOGIES, INC. | 2002-03-28 | — | — | US | disclosed |
| WO-2002000650-A2 | NOVEL COMPOUNDS POSSESSING ANTIBACTERIAL, ANTIFUNGAL OR ANTITUMOR ACTIVITY | GENELABS TECHNOLOGIES, INC. (US) | 2002-01-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030119749-A1 | Novel compounds possessing antibacterial, antifungal or antitumor activity | CYP51A1, MCL1, ERG28 | PLD2 3783/4885PLD1 2686/4885EGFR 923/4885 |
| US-20020037856-A1 | Novel compounds possessing antibacterial, antifungal or antitumor activity | CYP51A1, MCL1, ERG28 | PLD2 3783/4885PLD1 2686/4885EGFR 923/4885 |
| US-20030212113-A1 | Novel aromatic compounds and poly(oxyalkylene) containing aromatic compounds possessing antibacterial, antifungal or antitumor activity | TYR, CYP51A1, ODC1 | PLD2 4801/4885PLD1 4525/4885EGFR 212/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.